Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Not to Release 3-Year Mid-Term Business Plan, Changes to Annual Business Forecast
May 14, 2013
- Eisai Operating Profit Down 26%, Fails to Meet Revised Domestic Sales Target for Aricpet
May 14, 2013
- Daiichi Sankyo FY2012 Sales Up 6.3%; Leads Way with Near Double-Digit Growth in Japan Pharma Biz
May 14, 2013
- Four Leading Wholesalers See Clear Recovery in Pharmaceutical Wholesale Business
May 14, 2013
- DSP to Increase Latuda Sales Force to 450 in North America
May 13, 2013
- Yakult Pharmaceutical Sales and Profit Down as Elplat Sales Decline
May 13, 2013
- Millennium: Anna Protopapas Becomes President, R&D Functions Integrated into Takeda
May 13, 2013
- Ethical Drug Sales Down 0.7%, OTC Drug Sales Surge 8.9% in March: Crecon Report
May 13, 2013
- Meiji Seika Pharma Leads in Percentage of Female MRs with a Ratio of 1 Female to 3 MRs: Jiho Survey
May 13, 2013
- MTPC Royalties Reach 19.5 Billion Yen from Out-Licensed Gilenya
May 10, 2013
- Shionogi Chalks Up Record Profits as US Unit Buoys Sales
May 10, 2013
- DSP Sales Down 0.8% Due to Long-Listed Product Sales Decline, Double-Digit Growth in Profits
May 10, 2013
- Takeda Sees Sales Rise on Expanding Europe, Emerging Market Biz in FY2012, Yet Operating Profit Sags 50%
May 10, 2013
- No Prospects of Reaching Agreement on Delivery Prices with Wholesalers Even after the Fiscal Year End: Pres. Tajiri of Medical System Network
May 10, 2013
- Eisai to Launch the Obesity Treatment Belviq in the US in June
May 10, 2013
- Ono, DSP to Expand Business for Limaprost in China
May 10, 2013
- Santen’s FY2012 Operating Profit Sinks 7% as Eylea Launch Drives Up Cost Ratio
May 9, 2013
- Astellas Partners with Drais Pharmaceuticals to Develop Nocturia Treatment
May 9, 2013
- MTPC Annual Sales Up 3% with Gilenya Royalities, Remicade Growth
May 9, 2013
- Baxter’s Cell Culture-Based Prototype Flu Vaccine Obtains Approval
May 9, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…